Swiss National Bank cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,375,800 shares of the company’s stock after selling 309,900 shares during the quarter. Johnson & Johnson comprises about 1.1% of Swiss National Bank’s portfolio, making the stock its 11th biggest holding. Swiss National Bank owned approximately 0.40% of Johnson & Johnson worth $1,608,249,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wescott Financial Advisory Group LLC grew its position in Johnson & Johnson by 2.2% during the first quarter. Wescott Financial Advisory Group LLC now owns 10,565 shares of the company’s stock worth $1,638,000 after buying an additional 223 shares in the last quarter. Harfst & Associates Inc. lifted its position in shares of Johnson & Johnson by 14.2% during the 1st quarter. Harfst & Associates Inc. now owns 11,977 shares of the company’s stock valued at $1,856,000 after acquiring an additional 1,485 shares during the period. Tredje AP fonden grew its holdings in shares of Johnson & Johnson by 1.0% during the 1st quarter. Tredje AP fonden now owns 443,115 shares of the company’s stock worth $68,683,000 after purchasing an additional 4,270 shares in the last quarter. 25 LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $55,000. Finally, Allred Capital Management LLC raised its stake in Johnson & Johnson by 0.8% in the first quarter. Allred Capital Management LLC now owns 30,296 shares of the company’s stock valued at $4,696,000 after purchasing an additional 244 shares in the last quarter. 67.57% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.59 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.75 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Analysts Set New Price Targets
A number of analysts have recently weighed in on JNJ shares. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, August 17th. They set a “strong-buy” rating for the company. Credit Suisse Group upped their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Atlantic Securities raised their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $171.80.
Read Our Latest Research Report on JNJ
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- 3 Healthcare Dividend Stocks to Buy
- Bear Market vs Recession: What Are the Differences?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 7 Best AI Mutual Funds (and ETFs) to Sweep the AI Craze
- Investing in Blue-Chip Stocks
- Auto Parts Stocks Shift Gears: Which is the Right One to Buy?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
